ARKGvsXBIETF Comparison
VS
ARK Genomic Revolution ETF (ARKG) belongs to the BioTech & Genomics segment. State Street SPDR S&P Biotech ETF (XBI) is part of the US Health Care segment. ARKG's top 1 sector exposures are Healthcare. In contrast, XBI's top sector exposures are Healthcare and Finance. ARKG is more expensive with a Total Expense Ratio (TER) of 0.75%, versus 0.35% for XBI. ARKG is up 76.72% year-to-date (YTD) with +$90M in YTD flows. XBI performs worse with 27.02% YTD performance, and +$481M in YTD flows. Run a side-by-side ETF comparison of ARKG and XBI below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
ARKG vs XBI performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 10/27/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | ARKG XBI | -3.25%-1.15% | +36.71%+2.82% | +76.72%+27.02% | +65.56%+39.29% | +132.21%+142.93% | -29.90%+27.60% |
| Flows | ARKG XBI | +$37M+$160M | +$51M+$86M | +$90M+$481M | +$63M+$937M | -$431M-$469M | -$2.01B+$1.53B |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | ARKG XBI | +49.99%+30.76% | +44.59%+29.00% | +44.73%+28.39% | +46.89%+33.08% |
| Max drawdown | ARKG XBI | -17.81%-14.89% | -27.52%-14.89% | -46.41%-32.94% | -76.56%-53.28% |
| Max drawdown duration | ARKG XBI | 22d69d | 126d69d | 882d331d | 1818d1622d |
Trading data
ARKG | XBI | |
Last sale 10/28/2026 at 1:30 PM | $54.82 | $157.51 |
| Previous close 10/27/2026 | $51.65 | $154.84 |
| Consolidated volume 10/27/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of September 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
ARKG
is actively managed and doesn’t replicate an indexARKG | XBI | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 10/28/2026 at 1:30 PM
Live
Closed
ARKG | XBI | |
|---|---|---|
| Last price | $54.82 | $157.51 |
| 1D performance | +6.14% | +1.72% |
| AuM | $2.18 B | $10.34 B |
| E/R | 0.75% | 0.35% |
Characteristics
ARKG | XBI | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Ark Investment | State Street Investment Management |
| Benchmark | - | S&P Biotechnology Select Industry Index |
| N° of holdings | 31 | 149 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | April 2, 2019 | January 31, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
ARKG
USA
88.62%
Other
11.38%
XBI
USA
95.53%
Other
4.47%
Sectors
ARKG
Healthcare
97.89%
Other
2.11%
XBI
Healthcare
99.18%
Other
0.82%
Advertisement
Diversification
ARKG
Total weight of top 15 holdings out of 15
74.64%
XBI
Total weight of top 15 holdings out of 15
21.91%
Top 15 holdings
Data as of August 31, 2026
ARKG
10X Genomics, Inc.
9.58%
Twist Bioscience Corp.
9.13%
Tempus AI, Inc.
7.91%
CRISPR Therapeutics AG
6.10%
Personalis, Inc.
5.93%
Absci Corp.
4.88%
Natera, Inc.
4.06%
Illumina, Inc.
4.04%
Eli Lilly & Co.
3.86%
CareDx, Inc.
3.85%
Guardant Health, Inc.
3.81%
Beam Therapeutics, Inc.
3.56%
Compass Pathways Plc
3.17%
Recursion Pharmaceuticals, Inc.
2.44%
Adaptive Biotechnologies Corp.
2.32%
XBI
Moderna, Inc.
2.81%
Twist Bioscience Corp.
1.89%
Apogee Therapeutics, Inc.
1.50%
Kymera Therapeutics, Inc.
1.40%
Halozyme Therapeutics, Inc.
1.39%
Natera, Inc.
1.37%
Praxis Precision Medicines, Inc.
1.34%
Oruka Therapeutics, Inc.
1.33%
Revolution Medicines, Inc.
1.31%
Travere Therapeutics, Inc.
1.30%
Protagonist Therapeutics, Inc.
1.28%
Dianthus Therapeutics, Inc.
1.27%
CG Oncology, Inc.
1.26%
Vaxcyte, Inc.
1.23%
Erasca, Inc.
1.23%
Frequently asked questions about ARKG and XBI
How have the ARKG and XBI ETFs performed in 2026?
As of October 27, 2026, ARKG is up 76.72% year-to-date (YTD), while XBI has returned 27.02%. That puts ARKG better performer ahead so far this year.
Which ETF is attracting more investor money: ARKG or XBI?
Year-to-date, the ARKG ETF saw +$90M in flows, compared to +$481M for XBI.
Which ETF is more volatile: ARKG or XBI?
Over the past year, ARKG had a volatility of 44.59%, while XBI experienced 29%.
Which ETF is bigger: ARKG or XBI?
As of October 27, 2026, ARKG holds $2.18 B in assets under management (AUM), while XBI manages $10.34 B.
What sectors do the ARKG and XBI ETFs invest in?
ARKG leans toward sectors like Healthcare. Meanwhile, XBI focuses on Healthcare.
What are the top holdings of the ARKG ETF and XBI ETF?
ARKG top holdings include 10X Genomics, Inc., Twist Bioscience Corp. and Tempus AI, Inc.. XBI holds in its top three: Moderna, Inc., Twist Bioscience Corp. and Apogee Therapeutics, Inc..
Which ETF is more diversified: ARKG or XBI?
ARKG holds 31 securities with 74.64% of its assets in the top 15. XBI has 152 securities and a top 15 weight of 21.91%.
Advertisement
Latest news about ARKG & XBI
The Weekly ETF Market Monitor (October 19-23, 2026)
October 26, 2026
ARKG
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Advertisement
Biotech ETFs – Investing in Health Innovation
July 21, 2022
ARKG
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
ARKG
XBI
Advertisement
